Horizon Therapeutics announces positive data from OPTIC Phase 3 confirmatory clinical trial and OPTIC-X open-label extension clinical trial of Tepezza (teprotumumab-trbw) for thyroid eye disease

Company reports that 89% patients (33/37) who received placebo during OPTIC trial and then entered OPTIC-X and received teprotumumab, an IgG1k monoclonal antibody that binds to insulin-like growth factor-1, achieved primary endpoint of ≥ 2mm reduction in proptosis at week 24.


Biospace Inc.